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Smad4 is a candidate tumour-suppressor gene identified recently on chromosome 18q21.1. Both alleles are inactivated in nearly one-
half of pancreatic carcinomas, but its role in the tumorigenesis of other tumours is still unknown. The aim of this study was to
investigate the potential involvement of the Smad4 locus in early-stage colorectal cancers (stages I–III) in tumour samples from a
randomised multicentre trial. Of a large collection of DNA samples, 73 with a loss of one allele of the Smad4 gene were analysed for
the presence of point mutations in the remaining gene. Patients, from whom biopsies were isolated, were part of a previous
randomised multicentre study of the Swiss Group for Clinical Cancer Research on the benefit of adjuvant chemotherapy (SAKK study
40/81). Mutation analysis was restricted to the highly conserved C-terminal domain (exons 8, 9, 10 and 11) of Smad4, using PCR and
single-strand conformational variant analysis. Two of the 73 patients (3%) with loss of one allele of Smad4 had a point mutation in the
remaining allele. These results indicate that whereas Smad4 point mautations are prevalent in pancreatic carcinoma, they are
infrequent in early stages (I–III) of colorectal cancer.
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Deletion of a chromosomal region is a frequent cytogenetic alter-
ation observed in carcinogenesis. The loss of tumour-suppressor
genes has been reported in numerous types of human tumours, in
particular those of the gastrointestinal tract (Vogelstein et al,
1988). APC and p53 have been widely recognised as important
tumour-suppressor genes inactivated during colorectal carcino-
genesis. Several other tumour-suppressor genes have been located
on chromosomes 1p, 8p, 18q and 22q. In particular, loss of
heterozygosity (LOH) at 18q21 is correlated with carcinomas of the
colon, and other tumours such as pancreatic carcinoma, renal cell
carcinoma, melanoma and breast carcinoma (Schutte et al, 1996;
Barbera et al, 2000). Much of the interest in this region arose
because reports indicated that 18q losses are associated with high
metastatic potential and reduced patient survival (Iino et al, 1994).
In fact, several potentially cancer-related genes map to the 18q21
region, including bcl-2, gastrin-releasing peptide gene and cellular
homologue of yes-1. However, none of these have been observed to
be mutated in colorectal cancer (CRC). Fearon et al. (1990)
identified another tumour-suppressor gene localised on 18q21,
designated DCC for deleted in colorectal cancer. However, there
have been several cases in which loss of expression did not
correlate with LOH (Kikuchi-Yanoshita et al, 1992), and mutation
in the coding region of the DCC gene has been infrequently
detected (Cho et al, 1994; Sato et al, 2001). Owing to the
controversial evidence as to the role of DCC in cancer, additional
genetic analysis of the 18q21 region led to the identification of
other potential tumour-suppressor genes, including three candi-
date tumour-suppressor genes: Smad2, Smad4 and Smad7. These
genes are involved in signal transduction of the TGFb signalling
pathway. Members of the transforming growth factor (TGF)-b
family transmit their signals from the plasma membrane to the
nucleus through combinations of serine/threonine kinase recep-
tors and their downstream effectors, known as Smads. After the
Smad4 (MADH4) gene was isolated from the same region as a
tumour-suppressor gene for pancreatic cancer (Hahn et al, 1996),
mutation analysis of this gene has been carried out in various
cancers. In recent studies, Smad4 was identified as a genetic target
in pancreatic carcinomas, inactivated through homozygous dele-
tion (n¼5), intragenic mutation (n¼3) and lack of protein (n¼2)
in 10 out of 16 pancreatic cell lines (Barbera et al, 2000).
Furthermore, it could be shown that when genetically inactivated
this tumour-suppressor in the TGFb signalling pathway represents
a prognostic factor in invasive pancreatic cancer influenced by
Smad4 status (Tascilar et al, 2001). In addition to observations in
pancreatic carcinomas, Smad4 is also known as a gene involved in
juvenile polyposis tumour predisposition syndrome (Howe et al,
1998; Huang et al, 2000). Mutations of the Smad4 gene have been
detected in some colorectal cancers, but its role in this specific
cancer remains unclear. The frequencies of mutations (5–45%)
have been found to be low (Takagi et al, 1996; MacGrogan et al,
1997; Ohtaki et al, 2001), but data originated from relatively small
studies, and the tumour populations examined were inhomoge-
neous explaining the broad range of incidences found. Revised 21 October 2002; accepted 7 November 2002
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yThe aim of this study was to further expand these data by Smad4
mutation analysis of a large set of early-stage (I–III) colorectal
cancer patients treated in a randomised multicentre trial of
5-fluorouracil (5-FU)/Mitomycin C adjuvant chemotherapy of the
Swiss Group for Clinical Cancer Research (SAKK study 40/81).
Owing to the significance of LOH in colorectal cancer and the role
of the remaining gene, this study was focused on patients with an
allelic loss of one Smad4.
METHODS
Patients
Patients from whom biopsies were isolated, were part of a previous
randomised multicentre study of the SAKK on the benefit of
treatment with adjuvant chemotherapy between 1981 and 1987
(Laffer, 1995). Deoxyribo nucleic acid (DNA) samples of these
patients were extracted from tumour as well as from healthy tissue
derived from the same patient in order to perform genetic
analyses. Paraffin-embedded material was available from 329 of the
505 patients. To investigate genetic alterations in the 18q21 region
in these tumours, a gene dosage study of the tumour-suppressor
genes Smad2, Smad4 and DCC was performed (Boulay et al, 1999).
For technical reasons, high-quality DNA for analysis was available
from 294 patients only. Individual dosage of the Smad4 gene
showed a total deletion frequency (one or both alleles) of 68%
when compared to normal tissue. In total, 167 patients (¼57%)
were detected with an allelic loss of one Smad4 copy. In this study,
we randomly chose 73 of these 167 patients to search for the
presence of point mutations in the remaining gene. After analysis
of these 73 out of 167 patients, two point mutations of Smad4 had
been detected, and for statistical reasons, further mutation analysis
in the remaining 94 out of 167 patients did not seem necessary to
substantiate our finding.
Gene copy status scoring
Genomic samples from 294 patients were tested for copy dosage of
the Smad4 gene using TaqMan quantitative real-time PCR (Perkin-
Elmer, Huenenberg, Switzerland). Copy status of the Smad4 gene
was determined by comparing tumour DNA to DNA from normal
tissue derived from the same patient as described previously
(Boulay et al, 1999).
Duplex PCR
Polymerase chain reaction (PCR) amplification on DNA was
performed in 15ml reaction volume, containing 1.5ml1 0  PCR
buffer (Perkin-Elmer, Huenenberg, Switzerland), 10mM
20desoxyribonucleosoid-50-triphosphate (dNTPs), 20mM of each
primer, 1U of AmpliTaq Gold (Perkin-Elmer, Huenenberg,
Switzerland),
32P Oligo (2.5ml1 0  Buffer, 20mM forward primer,
1ml PNK and 1ml g32P-adenosine triphosphate (ATP) incubated
30min at 371C) and 100ng DNA. Duplex PCR for Smad4 gene was
done using primers EX 8/1 and EX 8/2, EX 9/1 and EX 9/2, EX 10/1
and EX 10/2, and finally EX 11/1 and EX 11/2 (Table 1).
Polymerase chain reaction conditions were as follows: 40
amplification cycles of denaturation at 941C for 45s, annealing at
551C for 60s, and extension at 721C for 60s, followed by one cycle
at 721C for 10min. Amplification products were loaded on a
0.4mm acrylamide gel in a ‘Model S2 Sequencing Gel Electro-
phoresis Apparatus (Life Technologies, Switzerland)’. Electrophor-
esis settings are: 1800V, 35–40mA, 60VA and 120min.
Polymerase chain reactions without DNA templates were per-
formed as negative controls. Bands were subsequently cut out from
the single-strand conformation polymorphism (SSCP)-gel and
reamplified in a PCR.
Sequencing analysis
Reamplification of DNA was performed in a 50ml reaction volume,
containing 5ml1 0  PCR buffer (Perkin-Elmer, Huenenberg,
Switzerland), 10mM dNTPs, 20mM forward and backward primer,
1U of AmpliTaq Gold (Perkin-Elmer, Huenenberg, Switzerland)
and 38mlH 2O. PCR conditions were as follows: 35 amplification
cycles of denaturation at 941C for 45s, annealing at 551C for 60s
and extension at 721C for 60s, followed by one cycle at 721C for
10min. Sequencing analysis was performed by Microsynth (Basel,
Switzerland) on a fluorescence-based DNA sequencer that utilises
capillary electrophoresis with 96 capillaries operating in parallel.
RESULTS
Among the 294 tumours for which gene dosage data (Smad2,
Smad4 and DCC) were available, 167 tumours (57%) showed
heterozygous loss of Smad4 (Boulay et al, 1999), and 73 out of 167
samples were randomly chosen for mutation analysis. Of these,
only two (3%) carried point mutations in Smad4 in tumour but not
the corresponding healthy tissue, as demonstrated by PCR–SSCP
(Figure 1). The two mutations were located in the highly conserved
C-terminal Smad4 homology region. One confirmed point muta-
tion was found in exon 9 and another point mutation in exon 11.
Both mutations were confirmed by direct sequencing analysis
showing one mutation resulting in an amino-acid change from
arginine to serine; the second mutation led to an exchange of
alanine to valine (Table 2).
However, a caveat in the interpretation of our data needs to be
mentioned: informative and reproducible data were available from
a total of 174 complete exons (8, 9, 10 and 11) derived from the 73
defined patients. This shortcoming of our data was because of
technical problems in the analysis, caused by the sometimes poor
quality of the DNA, as is often observed with nucleic acids isolated
from paraffin-embedded tissue. Nevertheless, since the exons for
which interpretable results were available were equally distributed
Table 1 Primer–sequences designed for duplex-PCR
Primer Forward Reverse
EX 8/1 50-GAAAGCCTTATATC TTTCTC-30 50CACGTATCCATCAACAGTAA-30
EX 8/2 50-TCCTTCAAGCTGCCCTATTG-30 50-CAATTTTTTAAAGTAACTATCTGA-30
EX 9/1 50-TATTAAGCATGCTATACAATCTG-30 50-GTGGTCACTAAGGCACCTGA-30
EX 9/2 50-TAAAGGTGAAGGTGATGTTT-30 50-CAAATAGAGCTTTAAGTCTA-30
EX 10/1 50-GTCAGGCATTGGTTTTTAATG-30 50-ATCCTGGGCCAGGGATGTTT-30
EX 10/2 50-AAACATCCCTGGCCCAGGAT-30 50-CAAAAATGTCATCATCCC AGT-30
EX 11/1 50-AAGAGATCACCCTGTCCCTCT-30 50-CCAGCAAGGTGTTTCTTTGA-30
EX 11/2 50-GGATTACCCAAGACAGAGCA-30 50-GTATTTTGTAGTCCACC ATC-30
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ybetween the eight different amplicons we used in our study, our
conclusion of a very low frequency of Smad4 point mutations in
the population studied is not put into question by this technical
shortcoming.
DISCUSSION
Smad proteins are a novel family of proteins that function
downstream of serine/threonine kinase receptors to transduce
signals for members of the TGFb superfamily (Massague, 1996).
The three Smads (Smad2, Smad4 and Smad7) encoded in the
18q21 chromosomal region participate in the signalling mechan-
isms subsequent to TGFb-receptor complex formation. Smad4, a
co-Smad of Smad2, is known as a tumour-suppressor gene in
different cancer types. Tumour-suppressor genes are often
inactivated when one allele acquires a mutation and the second
allele is lost, typically through deletion (Cavenee et al, 1983). The
tumour-suppressor gene p53 represents just one example for this
classic concept (Miller et al, 1992), while for another tumour-
suppressor gene, DCC, these findings could not be confirmed (Sato
et al, 2001). Our screen of 73 patients with early-stage colorectal
cancer (I–III) carrying a loss of one Smad4 allele identified two
mutations of the remaining allele (3%), a finding that is in
accordance with results described in the literature (Schutte et al,
1996; Miyaki et al, 1999).
Mutation analysis was restricted to exons 8, 9, 10 and 11 of
Smad4, which together span the entire conserved C-terminal
Smad4 homology region. Since 90% of the Smad4 mutations
reported are located in that highly conserved region, the number of
undetected mutations is expected to be low when the analysis is
restricted to these mutation hot spots (Hahn et al, 1996; Takagi
et al, 1996; Kong et al, 1997). The low rate of point mutations
detected by our method deserves further comments: SSCP has
been shown to be a highly sensitive method to identify mutations
in PCR-generated fragments. The sensitivity of SSCP analysis is
widely disputed in the literature, with reports ranging from 35%
(Sarkar et al, 1992) to nearly 100% (Orita et al, 1989). Of course,
certain mutations may not be detected using this method.
Furthermore, it is possible that some of our tumours had large
intragenetic deletions of Smad4, which would have been missed
with the detection method used. However, the single factor having
the greatest effect on SSCP sensitivity is the size of the DNA
fragments. An optimal size of 200 base pairs (bp) or less was used
in our study (160–180bp), which is described as the most sensitive
for single-base substitutions (Sheffield et al, 1993).
Among the mediators of TGFb signalling encoded by the 18q21
chromosomal region, two were identified as involved in activating
TGFb signalling: Smad2 and Smad4, and one, in the inhibition of
TGFb signalling: Smad7. Thus, one could have expected that
inactivation of Smad4 might result in a TGFb resistance that would
favour tumour expansion. Interestingly, the patients with deletion
of Smad4 did not show a significantly worse prognosis than those
without a deletion (Boulay et al, 2002). In contrast, in the same
population, Smad4 seemed to be a predictive marker for 5FU/
mitomycin adjuvant chemotherapy. However, whether Smad4
plays a key role in tumorigenesis of colorectal cancer is still
unclear.
To date, a significant number of Smad4 point mutations have
been found only in pancreatic carcinomas (50–60%), biliary tract
carcinomas (15%) or colorectal carcinomas (5–20%) (Hahn et al,
1996; Schutte et al, 1996; MacGrogan et al, 1997). Although the
existence of additional unknown target tumour-suppressor genes in
the region of 18q21 cannot be ruled out, recently published
results strongly suggest a significant contribution of Smad4 gene
inactivation in advanced tumour stages. Metastatic colorectal
carcinomas including carcinomas metastasised to the liver showed
a considerably higher frequency (31–35%) than invasive carcino-
maswithout distant metastasis (7%) (Miyaki et al, 1999; Ohtaki et al,
2001). Our findings of less than 5% point mutations are at the lower
end of the spectrum and confirm the low frequency of point
mutations of Smad4 in early-stage colorectal cancer without
distant metastasis. The limitation to patients with loss of one
Smad4 allele–initially used to select a population with a
presumably high mutation frequency–is one possible theoretical
explanation for our findings. However, in pancreatic and biliary
tract carcinomas, patients with LOH represent a group with an
especially high point mutation frequency in the remaining gene,
making this explanation highly unlikely (Hahn et al, 1998; Barbera
et al, 2000).
Other possible explanations for the absence of Smad4 point
mutations in colorectal cancer at this stage include methylation
changes at the promoter and alternative splicing or changes in
mRNA stability (Roth et al, 2000). The importance of genes that
undergo alterations at low prevalence, however, may as yet be
underestimated. Such events may contribute significantly to the
genetic variety within a tumour type and, thus, to the complexity
of human tumorigenesis. Since it is likely that many alterations of
low prevalence exist in human cancers, an individual tumour
might still acquire several of these different alterations with a high
probability, making low prevalence alterations a powerful driving
force of the carcinogenic process.
In conclusion, our findings indicate that Smad4 point mutations
are infrequent in early stages of colorectal cancer. However, it
cannot be completely ruled out that inactivation of Smad4 could be
a common genetic event at later stages of colorectal cancer.
Future research comparing early and advanced stages is
required to investigate the tumour-suppressor pathway in color-
ectal cancer and to redefine the role Smad4 signalling plays in
tumorigenesis.
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Figure 1 SSCP analysis of Smad4 in early-stage colorectal cancer.
Representative results of PCR–SSCP analysis using EX9/2f and EX9/2r
primers (exon 9). Patient No. 18 shows a migration alteration in tumour
DNA (T) compared to normal tissue DNA (N) defined as an SSCP,
whereas patient No. 25 does not display any polymorphism. Extra bands
( ) were subsequently cut out from the SSCP-gel and reamplified in a
PCR before subjected to sequencing analysis.
Table 2 Mutations of Smad4 gene detected in colorectal cancer
Patient Exon Alteration Effect
18 9 AGA-AGC Arginine (R)-Serine (S)
376 11 GCT-GTT Alanine (A)-Valine (V)
Two out of 73 patients (3%) with point mutations of Smad4.
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